Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.
- EligibilityCriteria: Group 1: wtATTR-CM patients  Inclusion Criteria:  Patients > 18 years diagnosed with ATTRwt-CM by: endomyocardial biopsy DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing. Informed oral and written consent  Exclusion Criteria:  AL amyloidosis (light-chain amyloidosis). Myelomatosis Waldenström macroglobulinemia  Group 2: Control group  Inclusion Criteria:  Patients > 18 years Informed oral and written consent  Exclusion Criteria:  Known cardiovascular disease including ischemic heart disease, heart failure, atrial fibrillation, presence of a pacemaker, or malignant hypertension. Well-controlled hypertension is acceptable. Suspicion of cardiac amyloidosis assessed through clinical history, physical examination, ECG, and echocardiography focusing on "red flags": Echocardiography with: Myocardial hypertrophy (septum >11 mm) Apical sparing in LV-GLS Infiltrative changes in the right ventricle free wall, thickened atrioventricular valves, or thickened atrial septum Symptoms of polyneuropathy Low voltage on ECG or discrepancy between left ventricular thickness and ECG amplitude indicative of low voltage Atrioventricular block (AV block) Bilateral carpal tunnel syndrome Surgery for spinal stenosis Elevated troponin I or NT-pro-BNP - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Including variating severity of wtATTR-CM by including 40 patients with NAC stage 1, 40 patients with NAC stage 2, and 20 patients with NAC stage 3. Furthermore, including a healthy control group in order to examine normal values of mis- and frag-TTR - SamplingMethod: Non-Probability Sample